Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Inclusion Criteria: Age ≥ 18 years and ≤ 75 years

• Severe or very severe recurrent vesicular hand eczema for a minimum duration of 3months as defined by a Physician Global Assessment (PGA) using a validated Photoguide

• Refractory to standard therapy, defined as: Patients received treatment with topical corticosteroids of class II or higher for at least 8 weeks within 3 months before enrolment, with either no response or a transient response.Patients had also received standard skin care, including emollients and barrier protectionas appropriate, without significant improvement. Patients had avoided irritants and contactallergens, if identified, without significant improvement.

• Women of childbearing potential are required to use at least two forms ofcontraception for at least 1 month before starting treatment, during treatment, andfor at least 1 month after finishing treatment; these women are required to takemonthly pregnancy tests

• Able to provide written Informed Consent

• Able to speak and read the Dutch language

Exclusion Criteria: General criteria prior to randomization

• Treated with alitretinoin or cyclosporine in the previous 3 months

• Other morphologic types of hand eczema as defined by the Danish Contact DermatitisGroup

• Patients with predominantly atopic dermatitis, in which the hands are also involved. (Patients with controlled atopic dermatitis, in which the hands are mainly affected,are eligible for inclusion.)

• Psoriasis of the hands

• Active bacterial, fungal, or viral infection of the hands

• Pregnant/lactating or planning to become pregnant during the study period

• Treatment with systemic medication or UV radiation within the previous 4 weeks

• Mentally incompetent

• Immunocompromised status

• Uncontrolled arterial hypertension (minimally 3 measurements). Systolic pressure > 160mmHg or diastolic pressure > 95 mmHg, despite starting anti-hypertensive medication (first choice amlodipine 5 mg/day)

• Known or suspected allergy to ingredients in the study medications

• Inclusion in a study of an investigational drug within 60 days prior to start oftreatment

• Current malignancy (other than successfully treated non-metastatic cutaneous squamouscell or basal cell carcinoma and⁄or localized carcinoma in situ of the cervix)

• Current active pancreatitis

• Evidence of alcohol abuse or drug addiction

• Malabsorption

• Currently active gout

• Recurring convulsions / epilepsy

• Living vaccine (including bacillus Calmette-Guérin (BCG), varicella, measles, mumps,rubella, yellow fever, oral polio and oral typhoid) in the last 2 weeks or the plannedapplication of such a vaccine during the study period

• Chronic or recurrent infectious diseases

• Contact sensitizations with clinical relevance to the hands, in which exposure toallergens is not avoided.

• Hypervitaminosis A due to the use of vitamin A supplements containing >2000 IU

• Use of drugs with potential to change the effective dosis of study drugs within theprevious 2 weeks Laboratory exclusion criteria post randomization

• Alanine aminotransferase (ALAT) and ⁄or aspartate aminotransferase (ASAT) values > 200% of the upper limit of normal

• Impaired renal function as indicated by a clinically relevant abnormal creatininevalue (to be determined by investigator or treating physician)

• Anemia as indicated by a clinically relevant lowered hemoglobin value (to bedetermined by investigator or treating physician) Alitretinoin specific

• Triglycerides > 200% of the upper limit of normal,

• Cholesterol or low density lipoprotein (LDL) cholesterol values > 200% of the upperlimit of normal

• Uncontrolled hypothyroidism (to be determined by investigator or treating physician) Cyclosporine specific:

• Impaired renal function as indicated by a clinically relevant abnormal creatininevalue (to be determined by investigator or treating physician)

• Uremia

• Hyperkalemia

• Hyperuricemia in patients with a medical history of gout